US 11919965
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11919965 (Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61P